Early career pharmacy researcher award (OPERA 2025)

My name is Zita Zachariah and I am the Managing Editor of the Royal Pharmaceutical Society research journals. I am reaching out since we felt that the members of the British Oncology Pharmacy Association may be interested to know that nominations for next year’s award OPERA2025 have now opened.

The OPERA award was launched in 2022 to celebrate contributions by up-and-coming researchers to the advancement of the science of medicines and clinical pharmacy. All shortlisted candidates for the OPERA award will be featured in the Pharmaceutical Journal and so this is a valuable platform for early career researchers to gain visibility in the pharmacy community.

OPERA nominations are

  • open to all UK based early-career pharmacy practice/pharmaceutical sciences/health services researchers,
  • all applications will be anonymised before judging and
  • self-nominations are welcome.

For more information see the link below

pharmaceutical-journal.com-Nominate an outstanding early-career pharmacy researcher for OPERA 2025

Best Regards

Zita

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article